CN115429820A - Application of lactobacillus acidophilus in preparation of product for reducing blood uric acid - Google Patents
Application of lactobacillus acidophilus in preparation of product for reducing blood uric acid Download PDFInfo
- Publication number
- CN115429820A CN115429820A CN202210533737.4A CN202210533737A CN115429820A CN 115429820 A CN115429820 A CN 115429820A CN 202210533737 A CN202210533737 A CN 202210533737A CN 115429820 A CN115429820 A CN 115429820A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus acidophilus
- product
- uric acid
- parts
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 66
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 66
- 229940039695 lactobacillus acidophilus Drugs 0.000 title claims abstract description 66
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 50
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229940116269 uric acid Drugs 0.000 title claims abstract description 47
- 230000001603 reducing effect Effects 0.000 title claims abstract description 25
- 210000004369 blood Anatomy 0.000 title claims abstract description 20
- 239000008280 blood Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title description 10
- 238000004321 preservation Methods 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims description 38
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 35
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 28
- 239000003223 protective agent Substances 0.000 claims description 23
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 14
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 14
- 229930010555 Inosine Natural products 0.000 claims description 14
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 14
- 229940029575 guanosine Drugs 0.000 claims description 14
- 229960003786 inosine Drugs 0.000 claims description 14
- 229920001353 Dextrin Polymers 0.000 claims description 13
- 239000004375 Dextrin Substances 0.000 claims description 13
- 235000019425 dextrin Nutrition 0.000 claims description 13
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 12
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 12
- 229940073490 sodium glutamate Drugs 0.000 claims description 12
- 244000068988 Glycine max Species 0.000 claims description 9
- 235000010469 Glycine max Nutrition 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 230000000593 degrading effect Effects 0.000 claims description 6
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 claims description 3
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 claims description 3
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 claims description 3
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 claims description 3
- GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- LTFMZDNNPPEQNG-UHFFFAOYSA-N deoxyguanylic acid Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(COP(O)(O)=O)O1 LTFMZDNNPPEQNG-UHFFFAOYSA-N 0.000 claims description 3
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 3
- 235000013928 guanylic acid Nutrition 0.000 claims description 3
- 239000004226 guanylic acid Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 235000013902 inosinic acid Nutrition 0.000 claims description 3
- 239000004245 inosinic acid Substances 0.000 claims description 3
- 229940028843 inosinic acid Drugs 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 235000013322 soy milk Nutrition 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- 229940074410 trehalose Drugs 0.000 claims description 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims description 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims 1
- 239000003833 bile salt Substances 0.000 abstract description 11
- 238000009629 microbiological culture Methods 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 description 22
- 238000006731 degradation reaction Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 201000001431 Hyperuricemia Diseases 0.000 description 12
- 108010093894 Xanthine oxidase Proteins 0.000 description 12
- 102100033220 Xanthine oxidase Human genes 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 201000005569 Gout Diseases 0.000 description 10
- 238000004108 freeze drying Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000010802 sludge Substances 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 240000006024 Lactobacillus plantarum Species 0.000 description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 4
- 241000186604 Lactobacillus reuteri Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 3
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 3
- 241000194020 Streptococcus thermophilus Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- VMWAQQDZRLEWAK-YOCMHDSMSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1.C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VMWAQQDZRLEWAK-YOCMHDSMSA-N 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 229950000193 oteracil Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000191998 Pediococcus acidilactici Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- SPOMEWBVWWDQBC-UHFFFAOYSA-K tripotassium;dihydrogen phosphate;hydrogen phosphate Chemical compound [K+].[K+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O SPOMEWBVWWDQBC-UHFFFAOYSA-K 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to an application of Lactobacillus acidophilus (Lactobacillus acidophilus) in preparing a product for reducing blood uric acid, wherein the preservation number of the Lactobacillus acidophilus is CGMCC No.23546, the preservation unit is the China general microbiological culture Collection center, the preservation date is 2021 year, 10 month and 9 days, and the preservation address is No. 3 of No.1 Xilu Beijing Kogyo of the sunward area in Beijing. The lactobacillus acidophilus can survive under the conditions of low pH and bile salt and has remarkable capacity of reducing blood uric acid.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and relates to application of lactobacillus acidophilus in preparation of a product for reducing blood uric acid.
Background
Hyperuricemia and ventilation are chronic diseases, and the level of fasting serum uric acid is more than 420 mu mol/L for 2 times on non-same day under normal purine diet state in both men and women. Uric acid is a product of purine metabolism in the human body. Normally, uric acid in the body is about 1200mg, and is excreted at about 800-1000 mg per day, with 70% excreted by the kidney and 30% excreted by the intestine. Hyperuricemia and gout are considered to be caused by excessive uric acid synthesis in the body or uric acid excretion disorder in the kidney and intestinal tract. Excessive intake of purine foods such as beer, seafood, animal viscera and the like is easy to increase the content of blood uric acid, and hyperuricemia and gout are easily caused by kidney and intestinal tract excretory obstruction. A large number of clinical observations and tests prove that hyperuricemia and ventilation easily cause complications such as hypertension, fatty liver, chronic nephropathy, cardiovascular diseases and the like. According to statistics, hyperuricemia shows a remarkable rising and young trend, the total morbidity of the hyperuricemia is about 13.3 percent, the number of patients is about 1.77 hundred million, the total morbidity of gout is 1.1 percent, and the number of the patients is about 1466 ten thousand.
At present, there are two main types of methods for treating and preventing hyperuricemia and gout, one is a drug therapy method, such as allopurinol, benzbromarone, colchicine, etc.; the other is a purine diet method, which reduces the intake of purine foods, such as seafood, animal dryness, beer, etc. However, the side effects of the drug therapy are more, which can cause damage to liver and kidney functions, damage to gastrointestinal tracts, increase the death risk of cardiovascular system, diarrhea, rash and the like, and can not be used excessively and for a long time; the purine diet restriction method cannot follow the purine diet for a long time because all animals and plants contain purine substances and the main ingredient of flavor-forming agent in the food is purine substances. By analyzing the structural composition of the intestinal flora by using a 16S rRNA sequencing method, the Zhang Heping professor team of inner Mongolia agricultural university finds that the diversity of the intestinal flora alpha in the intestinal tract of patients with hyperuricemia and gout is different from that of healthy people, and shows a remarkable reduction, which indicates that the intestinal flora participates in the pathogenesis of gout. Therefore, the microecological therapy for regulating the intestinal flora of the human body provides a new method for preventing hyperuricemia and gout.
Hundreds of millions of bacteria live in the human intestinal tract, and most of the bacteria live in symbiosis with the human body and form a unique microecological system. Lactic acid bacteria are the most important probiotics in human intestinal tracts, and play an important role in maintaining the microecological balance of the human intestinal tract environment. The Cao Tong et al at Qingdao university intervene by using bifidobacterium and lactobacillus fermentum to reduce the generation of uric acid, reduce the activity level of serum endotoxin and xanthine oxidase and reduce the serum uric acid level. The lactobacillus reuteri WX-94 which has stress resistance and can reduce uric acid is screened out by the university of inner Mongolia agriculture, namely the Roche. Therefore, the screening of the compound has high stress resistance, reduces the absorption of uric acid in intestinal tracts and is vital to increase the excretion of uric acid in the intestinal tracts.
In conclusion, the method for preventing and treating hyperuricemia or gout by increasing the degradation of urea in vivo by intestinal probiotics becomes a safe, healthy and sustainable method. However, the strategies for reducing blood uric acid by using probiotic intervention disclosed in the prior art are quite limited, and the blood uric acid reducing effect of related probiotics and products thereof is still to be improved, so how to provide a probiotic product with an excellent blood uric acid reducing effect is of great significance for preventing or treating hyperuricemia or gout.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide the application of lactobacillus acidophilus in preparing a product for reducing blood uric acid.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the invention provides an application of lactobacillus acidophilus in preparing a product for reducing blood uric acid, wherein the preservation number of the lactobacillus acidophilus is CGMCC No.23546.
Specifically, the Lactobacillus acidophilus is named as Lactobacillus acidophilus (LA 05), the preservation unit is the China general microbiological culture Collection center, the preservation number is CGMCC No.23546, the preservation date is 2021 year, 10 month and 9 day, and the preservation address is No. 3 of Western No.1 Hospital of sunward area, beijing.
Preferably, in the product for reducing the uric acid, the viable count of the lactobacillus acidophilus is not less than 1 x 10 8 CFU/g。
Preferably, the product comprises a food, health product or pharmaceutical product.
Preferably, the dosage form of the drug comprises a solution, a tablet, a capsule or a granule.
Preferably, the medicament further comprises pharmaceutically acceptable auxiliary materials.
Preferably, the adjuvant includes any one or a combination of at least two of diluent, flavoring agent, binder, excipient or filler, such as a combination of diluent and flavoring agent, a combination of excipient and filler, a combination of flavoring agent and binder, and the like, in any other combination.
In a second aspect, the invention provides an application of lactobacillus acidophilus freeze-dried powder in preparation of a product for reducing uric acid, wherein the preservation number of lactobacillus acidophilus is CGMCC No.23546, and the preparation raw materials of the lactobacillus acidophilus freeze-dried powder comprise lactobacillus acidophilus and a protective agent;
the protective agent comprises any one or combination of at least two of skimmed milk powder, soybean milk powder, resistant dextrin, sodium glutamate, trehalose, sucrose or inulin, wherein the combination of at least two of the skimmed milk powder and the soybean milk powder is adopted as the protective agent, the combination of the soybean milk powder and the resistant dextrin is adopted as the protective agent, the combination of the resistant dextrin and the sodium glutamate is adopted as the protective agent, the combination of the sodium glutamate and the trehalose is adopted as the protective agent, and any other combination mode can be adopted.
Preferably, the protective agent comprises soybean milk powder, resistant dextrin and sodium glutamate.
Preferably, the protective agent comprises 4-8 parts of soybean milk powder, 2-6 parts of resistant dextrin and 1-3 parts of sodium glutamate by weight.
Specific examples of the above-mentioned 4 to 8 parts include 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts and the like.
Specific examples of the above-mentioned 2 to 6 parts include 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts and the like.
Specific values in the above range of 1 to 3 parts are, for example, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts and the like.
Preferably, the mass ratio of the lactobacillus acidophilus to the protective agent is (1-10) to (1-10).
Specific numerical values in the above (1-10) are, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and the like.
Preferably, the product comprises a food, a nutraceutical or a pharmaceutical product.
In a third aspect, the invention provides an application of lactobacillus acidophilus in preparing a medicament for degrading purine precursors, wherein the lactobacillus acidophilus has a preservation number of CGMCC No.23546, and the purine precursors comprise any one or a combination of at least two of inosine, deoxyinosine, inosinic acid, deoxyinosinic acid, guanosine, deoxyguanosine, guanylic acid or deoxyguanylic acid.
The invention also provides application of lactobacillus acidophilus (with the preservation number of CGMCC No. 23546) in preparing products for degrading purine precursors for non-diagnosis or treatment, wherein the purine precursors comprise any one or combination of at least two of inosine, deoxyinosine, inosinic acid, deoxyinosinic acid, guanosine, deoxyguanosine, guanylic acid or deoxyguanylic acid.
Such as studies relating to the mechanism of degradation of purine precursors, studies relating to the physiological activities or pathological studies of the degradation pathways of purine precursors, and the like.
In a fourth aspect, the invention provides an application of lactobacillus acidophilus in preparing xanthine oxidase inhibitors, wherein the preservation number of the lactobacillus acidophilus is CGMCC No.23546.
The invention also provides application of lactobacillus acidophilus (with the preservation number of CGMCC No. 23546) in preparing a product for inhibiting xanthine oxidase for the purpose of non-diagnosis or treatment.
Such as the research on the action mechanism of xanthine oxidase, the research on activity influencing factors, etc.
The recitation of numerical ranges herein includes not only the above-recited values, but also any values between any of the above-recited numerical ranges not recited, and for brevity and clarity, is not intended to be exhaustive of the specific values encompassed within the range.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively provides the application of lactobacillus acidophilus LA05 in preparing a product for reducing blood uric acid. (1) The lactobacillus acidophilus LA05 has strong low pH resistance and bile salt resistance and uric acid reducing capacity, can survive under extreme conditions of pH =2 and 0.3% of bile salt concentration, has the survival rate of 130.3% under the condition of pH =2, and has the survival rate of 90.5% under the condition of 0.3% of bile salt. (2) The degradation capability of the compound on purine precursors (guanosine and inosine) is strong, the degradation speed of guanosine is 0.04491 mmol/(L.min), and the degradation rate is 100%; the degradation speed of inosine is 0.04541 mmol/(L.min), the degradation rate is 100%, and the degradation capability is obviously stronger than that of other strains (such as lactobacillus reuteri, lactobacillus johnsonii, lactobacillus plantarum and the like) with the capability of degrading or absorbing nucleoside in the prior art. (3) The lactobacillus acidophilus LA05 and the metabolite thereof can obviously inhibit the xanthine oxidase activity and have the same effect as allopurinol under the appropriate dosage. (4) The effect test of reducing blood uric acid in an animal model shows that the effect of the lactobacillus acidophilus LA05 on reducing blood uric acid is obviously stronger than that of other single strains or combination of strains under the condition of the same dosage, and the lactobacillus acidophilus LA05 can be used for preparing products for reducing blood uric acid. In addition, in practical application, the advantage of using a single strain is obvious, the problems that multiple strains are easy to contaminate, the processing is complicated, the action mechanism is unclear and the like are solved, and the single strain is more convenient to operate, convenient to control, difficult to contaminate and easy to industrially produce.
In conclusion, the lactobacillus acidophilus LA05 which can survive under the conditions of low pH and bile salt and has the capacity of reducing blood uric acid provides a new method for treating blood uric acid and gout, and compared with a clinical chemical medicine treatment mode, the lactobacillus acidophilus LA05 and the preparation thereof have the advantages of no toxic or side effect, higher safety and wide application prospect.
In addition, the protective agent used when the lactobacillus acidophilus LA05 is prepared into freeze-dried powder has certain influence on the survival rate of the strain, compared with other choices, the specific combination of resistant dextrin, soybean milk powder and sodium glutamate is adopted as the freeze-drying protective agent, so that the loss of the lactobacillus acidophilus LA05 in the freeze-drying process can be minimized, and the freeze-dried powder can fully exert the effect.
Detailed Description
In order to further illustrate the technical means and effects of the present invention, the technical solutions of the present invention are further described below with reference to the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
In the following examples, unless otherwise specified, reagents and consumables were purchased from conventional reagent manufacturers in the field; unless otherwise indicated, all experimental methods and technical means are those conventional in the art.
Example 1
Evaluation of degradation ability of Lactobacillus acidophilus LA05 for guanosine and inosine
Nucleoside uptake is the major route of purine and pyrimidine entry into the intestinal epithelium, and by degrading or absorbing nucleosides, the uptake of nucleosides by the intestinal epithelium is competitively reduced, thereby reducing the production of uric acid. Therefore, the degradation rate of the test strain on guanosine and inosine can fully reflect the capability of the strain for reducing blood uric acid.
The strains to be tested are as follows: lactobacillus acidophilus LA05, lactobacillus casei LC89 (CGMCC No. 15409), lactobacillus paracasei LC86 (CGMCC No. 1.12731), lactobacillus salivarius LS97 (CGMCC No. 169922), streptococcus thermophilus ST81 (CGMCC No. 15752), lactobacillus plantarum Lp90 (CGMCC No. 10453), lactobacillus bulgaricus LB42 (CGMCC No. 15751), pediococcus acidilactici CCFM7902 (CGMCC No. 5493), lactobacillus gasseri LG08 (CGMCC No. 16131) and Bifidobacterium longum BL21 (CGMCC No. 10452).
Inoculating Bifidobacterium longum in BS liquid culture medium, inoculating the rest strains in MRS liquid culture medium, activating, inoculating the activated seed solution in 5% of inoculum size, culturing in MRS culture medium, and performing facultative anaerobic (standing) or strict anaerobic (oxygen concentration) culture at 37 deg.C<0.5%) for 8-20 hr (based on strain reaching stationary phase), centrifuging the obtained culture solution at 6000r/min for 30min, washing with physiological saline for 2 times, and adjusting thallus density to 1.5 × 10 11 And CFU/g, respectively adding guanosine standard solution and inosine standard solution with the same volume, uniformly mixing by shaking, culturing at 37 ℃ for 60min, centrifuging at 6000r/min for 30min, uniformly mixing 900 mu L of supernatant with 100 mu L of terminator, filtering by using a filter membrane with the pore diameter of 0.22 mu m, and then taking 20 mu L of supernatant for HPLC analysis. The degradation rate is calculated according to equation (1): v = (C) 0 -C)/60,V: degradation rate mmol/(L.min); c 0 : initial concentration mmol/L of guanosine (inosine) standard solution; c: concentration of remaining guanosine (inosine) standard solution mmol/L. The degradation rate α is calculated according to the formula (2): α (%) = (C) 0 -C)/C 0 ×100。
Drawing of standard curve
0.9mL of guanosine and inosine standard solutions were separately added to 0.1mL of a reaction terminator (0.1 mol/L HClO) 4 ) And (5) oscillating and blending the hooks. 20 mu L,15 mu L,10 mu L and 5 mu L are respectively sucked for sample injection analysis, and standard curve determination is carried out by an external standard method.
Chromatographic conditions are as follows: LC-2030 liquid chromatograph, reverse phase chromatography column: YMC-Triart C18 (4.6X 250 mm), mobile phase 50mmol/L KH 2 PO 4 -K 2 HPO 4 (pH 6.8), flow rate 0.425mL/min, wavelength 260nm, guanosine analysis time 75min, inosine analysis time 65min. The results are as follows:
TABLE 1 degradation of guanosine by the strains
TABLE 2 degradation of inosine by the strains
Table 1 shows that the degradation rates of guanosine of LA05, lp90, LG08 and BL21 are higher, wherein the degradation rate of guanosine of LA05 is 100%, the degradation rate of guanosine is 0.04491 mmol/(L.min), which is higher than that of Lactobacillus reuteri with the capability of degrading or absorbing nucleoside reported in the Roy Peng publication at the university of Mongolia agriculture in the past, 0.0423 mmol/(L.min) and 0.0390 mmol/(L.min) of Lactobacillus plantarum. As can be seen from table 2, inosine degradation rates of LA05, lp90, LG08 and BL21 are high, where the inosine degradation rate of LA05 is 100%, and the inosine degradation rate is 0.04541 mmol/(L · min), which is higher than that of the strain with nucleoside degradation or absorption ability reported by trepeng et al at the university of inner mongolia: lactobacillus reuteri 0.0423 mmol/(L.min), lactobacillus johnsonii 0.0423 mmol/(L.min), lactobacillus plantarum 0.0288 mmol/(L.min).
Example 2
Evaluation of acid and bile salt resistance of Lactobacillus acidophilus LA05
Probiotics only act when reaching the intestinal tract through the stomach, and in most cases, the pH of gastric juice of a human body is =3, and the emptying time is 2-3h. Meanwhile, in the process of digesting food by food, bile juice also plays a key role, and the concentration of bile in a human body is 0.1g-3g/L. Thus, this example evaluates the acid and bile salt tolerance of Lactobacillus acidophilus LA05 to determine whether the strain is able to grow and function normally in the gastrointestinal tract.
After activating LA05, lp90, LG08 and BL21 strains, the strains were inoculated in an MRS liquid medium with pH =2 and an MRS liquid medium containing 0.3% bile salt at 5% inoculum size, respectively, and cultured at 37 ℃ for 3 hours. Reference is made to GB 4789.35-2016 by dilution plate counting. The survival rate of the strain was calculated according to the formula (3): the survival rate of the strain (%) =3h viable cell count/0 h viable cell count × 100%. The results are as follows:
table 3 survival of strains under pH =2 conditions
TABLE 4 survival of the strains under 0.3% bile salt conditions
As can be seen from table 3, LA05, lp90 and BL21 all survived well under pH =2, whereas LG08 survived only 30.2% at a low rate. It can be seen from table 4 that the survival rate of LA05 was the highest at 0.3% bile salt concentration, which was 90.4%. The result fully proves that the lactobacillus acidophilus LA05 has strong acid and bile salt resistance, can ensure normal growth in intestinal tracts and plays a role.
Example 3
Evaluation of the ability of Lactobacillus acidophilus LA05 to inhibit xanthine oxidase Activity
Preparation of bacterial cell metabolites (CFS) and intracellular lysates (CFE): inoculating activated strains LA05, LP90 and BL21 into MRS liquid culture medium at 5%, and performing facultative anaerobic (standing) or strict anaerobic (oxygen concentration) treatment at 37 deg.C<0.5%) to a stationary phase, and centrifuging the obtained culture solution at 12000r/min for 15min to collect the bacterial pellet. Washing thallus precipitate with sterile normal saline for 2-3 times, re-suspending in normal saline, and regulating bacteria liquid concentration to 1.5 × 10 11 CFU/mL, mix well. Incubating at 37 deg.C for 12h, centrifuging at 12000r/min for 15min, collecting supernatant, and filtering with 0.22 μm microfiltration membrane to obtain thallus cell metabolite. Mixing 1.5X 10 11 And (5) performing ultrasonication on CFU/mL bacterial solution for 10min under the conditions that the power is 200W, the work time is 5s, and the stop time is 5 s. Centrifuging the liquid obtained after ultrasonic treatment at 12000r/min for 15min, collecting supernatant, filtering with 0.22 μm microfiltration membrane to obtain intracellular lysate, and storing at-80 deg.C for use.
The enzyme activity is measured according to the uric acid generation method in the published literature, and the specific steps are as follows:
xanthine and oxygen generate uric acid and superoxide anion under the action of xanthine oxidase, and uric acid has characteristic absorption peak at 295nm, so that the enzyme activity is calculated by the increase of absorbance at 290nm per minute, and the total time is recorded for 5min. The reaction system was 5mL, xanthine 1.5mL, xanthine oxidase 2mL, PBS (pH 7.5), samples of the same concentration and different volumes were added, and the blank was PBS (pH 7.5) instead of the enzyme solution. And calculating the inhibition rate of the sample on the xanthine oxidase, wherein the inhibition rate (%) = (1-B/A) × 100. Wherein A: blank group; b: and (4) sample group. And additionally setting a positive group: the samples were replaced with equal volumes of allopurinol, and the other samples were in the same group.
The results are as follows:
TABLE 5 inhibitory Effect of CFS strain on xanthine oxidase
TABLE 6 inhibition of xanthine oxidase by Strain CFE
It is seen from tables 5 and 6 that both the cell metabolites (CFS) and the intracellular lysate (CFE) of the strains LA05, lp90 and BL21 have an inhibitory effect on xanthine oxidase, and that the inhibitory activity is increased with the amount added. Wherein the cell metabolite (CFS) and intracellular solute (CFE) of LA05 have the strongest inhibition effect on xanthine oxidase, and can reach the level of a positive group when the addition amount is more than 0.2 mL.
Example 4
Evaluation of the Effect of Lactobacillus acidophilus LA05 on serum uric acid levels in model animals
48 male SD rats of 6-8 weeks old are selected, the weight of the rats is 150-180g, the rats are randomly divided into 8 groups, the 1 st group is a control group, the 2 nd group is a model group, the 3 rd-5 th group is a single strain treatment group, and the 6 th-8 th group is two composite strain treatment groups. The feeding and drinking of the rats during the experiment was not limited by any factors. Group 1 was a normal control group, and rats were given only commercial basal diet, free water, for 7 days. Group 2 model group the feed to rats was made with 2% uric acid, 4% oteracil potassium in a basal commercial ration for 7 days. In the treatment groups of groups 3-8, 2% uric acid and 4% potassium oxonate were added to the feed of rats on the first 3 days, and 1mL of a single bacterial solution (200 hundred million total viable bacteria) or a mixed bacterial solution of two bacterial strains (ratio of 1. On days 0, 3 and 7 of the experiment, blood was collected from the tail vein of the rat, centrifuged at 2000r/min, and serum was obtained and stored at-80 ℃. The result of using the Wuhansheng source uric acid detection kit to determine the serum uric acid concentration of the rat is as follows:
TABLE 7 serum uric acid concentration Change in various groups of rats
As can be seen from Table 7, each group of strains or combination of strains was able to reduce serum uric acid levels in rats. The single strains LA05, lp90 and BL21 and the mixed strains LA05+ Lp90, lp90+ BL21 and BL21+ LA05 (the mixing ratio is 1). Compared with other single strains or mixed strains, the single strain LA05 has the strongest serum uric acid reducing capability compared with the single strain or the mixed strains, wherein LA05> Lp90> BL21, and LA05+ Lp90+ BL21+ BL 05 in the single strain are mixed.
Example 5
Lactobacillus acidophilus LA05 freeze-dried powder
(1) Preparation of lactobacillus acidophilus LA05 freeze-dried powder
Inoculating lactobacillus acidophilus LA05 into an MRS liquid culture medium, culturing for 18h at 37 ℃ for activation, continuously activating for two generations to obtain an activated solution, inoculating the activated solution into the MRS liquid culture medium according to the inoculation amount of 2% (v/v), culturing for 18h at 37 ℃ to obtain a bacterial solution, centrifuging the bacterial solution for 10min at 7000g to obtain bacterial sludge, washing the bacterial sludge for 3 times by using physiological saline, then resuspending the bacterial sludge by using a protective agent solution (the mass percentage of the protective agent is 12%, and the balance is water) to obtain a mixed solution, uniformly mixing the bacterial sludge and the protective agent according to the proportion of 1 (w/w), and freeze-drying the mixture. The freeze drying process comprises a prefreezing stage, a primary drying stage and an analysis drying stage, wherein the prefreezing is carried out on a control laminate, the temperature of the control laminate is set to be 45 ℃ below zero, the control laminate is kept for 4 hours, the primary drying is carried out on the control laminate for 2 hours, the temperature is increased to be 25 ℃ below zero, the control laminate is kept for 30 hours, the analysis drying is carried out on the control laminate for 1 hour, the temperature is increased to be 25 ℃, the analysis drying is carried out for 15 hours, and the lactobacillus acidophilus LA05 freeze-dried powder is obtained.
Note: the proportion of the protective agent and the bacterial sludge can be correspondingly adjusted according to the specific requirements on the number of live bacteria in the freeze-dried powder product in the production process.
(2) Influence of protective agent on survival rate of strains in freeze-dried powder
Resistant dextrin was purchased from Yonglibao, soymilk powder from Longwang, skim milk powder from Hengheng, sodium glutamate from Huheng, trehalose from Runfeng chemical, sucrose from Juxin chemical, and inulin from Weilefu.
Respectively preparing lactobacillus acidophilus LA05 freeze-dried powder by using different protective agent formulas according to the method, measuring the number of viable bacteria in the freeze-dried powder and the corresponding mixed liquid before freeze-drying, and calculating the freeze-drying survival rate: freeze-drying survival = number of viable cells after freeze-drying/number of viable cells before freeze-drying, results are as follows:
TABLE 8
The results show that the specific combination of resistant dextrin + soy milk powder + sodium glutamate as lyoprotectant minimizes the loss of lactobacillus acidophilus LA05 during the lyophilization process, compared to other options.
Example 6
The embodiment provides a yoghourt containing lactobacillus acidophilus LA05, which is prepared by the following steps:
mixing whole milk powder/skimmed milk powder 200g, glucose 20g, xylitol 10g, and Streptococcus thermophilus ST81 lyophilized powder (1 × 10 mg) 11 CFU/g), 0.1mg Lactobacillus bulgaricus LB42 freeze-dried powder (1X 10) 10 CFU/g), 0.1mg Lactobacillus acidophilus LA05 lyophilized powder (1X 10) 11 CFU/g) to obtain yoghurt powder, dissolving in 1L sterile warm water, stirring, fermenting at 37 deg.C for 10-12 hr, and refrigerating at 4 deg.C for storage after yoghurt is solidified.
The preparation methods of the lactobacillus bulgaricus LB42 freeze-dried powder and the streptococcus thermophilus ST81 freeze-dried powder refer to the preparation method of the lactobacillus acidophilus LA05 freeze-dried powder (the formula of the protective agent is unified as resistant dextrin, soybean milk powder and sodium glutamate, and the weight ratio is 6.
Example 7
The present embodiment provides a solid beverage containing lactobacillus acidophilus LA05, which has a formula: calculated by weight parts, polyatomic alcohol50 parts of glucose, 20 parts of resistant dextrin, 27 parts of fructo-oligosaccharide and freeze-dried powder (1 × 10) of lactobacillus acidophilus LA05 11 CFU/g) 3 parts. Mixing the above materials, sealing and packaging.
Example 8
This example provides a chewable tablet containing lactobacillus acidophilus LA05, formulated as follows: by mass percentage, 20% of starch, 20% of maltodextrin, 1% of citric acid, 1% of magnesium stearate, 20% of sucrose, 10% of lactose, 20% of mannitol, 0.5% of ethanol water solution with volume fraction of 50%, and freeze-dried powder (1 × 10) of lactobacillus acidophilus LA05 11 CFU/g)7.5％。
Pulverizing the above materials, sieving with 50 mesh sieve, mixing, slowly adding 50% ethanol, stirring, and tabletting with single punch tablet machine to obtain chewable tablet.
The applicant states that the application of lactobacillus acidophilus in preparing a product for reducing uric acid is illustrated by the above examples, but the invention is not limited to the above examples, which does not mean that the invention must be implemented. It should be understood by those skilled in the art that any modifications of the present invention, equivalent substitutions of the raw materials of the product of the present invention, and the addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
Claims (10)
1. The application of lactobacillus acidophilus in preparing a product for reducing blood uric acid is characterized in that the lactobacillus acidophilus has a preservation number of CGMCC No.23546.
2. The use according to claim 1, wherein the viable count of the lactobacillus acidophilus in the product for reducing uric acid is not less than 1 x 10 8 CFU/g。
3. Use according to claim 1 or 2, wherein the product comprises a food, health product or pharmaceutical product;
preferably, the dosage form of the medicine comprises a solution, a tablet, a capsule or a granule;
preferably, the medicine further comprises pharmaceutically acceptable auxiliary materials;
preferably, the adjuvant comprises any one or a combination of at least two of diluents, flavoring agents, binders, excipients or fillers.
4. The application of the lactobacillus acidophilus freeze-dried powder in preparing the product for reducing the uric acid is characterized in that the lactobacillus acidophilus has the preservation number of CGMCC No.23546, and the lactobacillus acidophilus freeze-dried powder is prepared from the raw materials of lactobacillus acidophilus and a protective agent;
the protective agent comprises any one or the combination of at least two of skimmed milk powder, soybean milk powder, resistant dextrin, sodium glutamate, trehalose, sucrose or inulin.
5. The use of claim 4, wherein the protective agent comprises soy milk powder, resistant dextrin and sodium glutamate.
6. The use as claimed in claim 5, wherein the protective agent comprises, in parts by weight, 4-8 parts of soybean milk powder, 2-6 parts of resistant dextrin and 1-3 parts of sodium glutamate.
7. The use of any one of claims 4 to 6, wherein the ratio of the Lactobacillus acidophilus to the protective agent is (1-10) to (1-10) by mass.
8. Use according to any one of claims 4 to 7, wherein the product comprises a food, health product or pharmaceutical product.
9. The application of lactobacillus acidophilus in preparing a medicine for degrading purine precursors is characterized in that the lactobacillus acidophilus has the preservation number of CGMCC No.23546, and the purine precursors comprise any one or combination of at least two of inosine, deoxyinosine, inosinic acid, deoxyinosinic acid, guanosine, deoxyguanosine, guanylic acid or deoxyguanylic acid.
10. The application of lactobacillus acidophilus in preparing xanthine oxidase inhibitor is characterized in that the preservation number of the lactobacillus acidophilus is CGMCC No.23546.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210533737.4A CN115429820A (en) | 2022-05-16 | 2022-05-16 | Application of lactobacillus acidophilus in preparation of product for reducing blood uric acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210533737.4A CN115429820A (en) | 2022-05-16 | 2022-05-16 | Application of lactobacillus acidophilus in preparation of product for reducing blood uric acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115429820A true CN115429820A (en) | 2022-12-06 |
Family
ID=84241466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210533737.4A Pending CN115429820A (en) | 2022-05-16 | 2022-05-16 | Application of lactobacillus acidophilus in preparation of product for reducing blood uric acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115429820A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115960775A (en) * | 2023-02-28 | 2023-04-14 | 吉林大学 | Lactobacillus salivarius for improving production performance of gosling and resisting gout |
| CN117286077A (en) * | 2023-11-20 | 2023-12-26 | 微康益生菌(苏州)股份有限公司 | Probiotics for preventing and treating acute radioactive intestinal injury and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109170917A (en) * | 2018-09-26 | 2019-01-11 | 广州市健全家源信息科技有限公司 | The compound of creatinine in a kind of reduction blood |
| CN110079476A (en) * | 2019-04-24 | 2019-08-02 | 杭州娃哈哈科技有限公司 | One plant of lactobacillus fermenti that can reduce blood uric acid |
| WO2019203827A1 (en) * | 2018-04-19 | 2019-10-24 | Kibow Biotech Inc . | Composition and method for preventing or treating hyperuricemia or gout |
| CN113040363A (en) * | 2021-04-13 | 2021-06-29 | 青岛科技大学 | Seasoning with gout resisting function prepared by fermenting lactobacillus acidophilus |
| CN113215012A (en) * | 2020-01-21 | 2021-08-06 | 宁波倍益嘉生物科技有限公司 | Probiotic strain for reducing blood uric acid, composition and application thereof |
-
2022
- 2022-05-16 CN CN202210533737.4A patent/CN115429820A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019203827A1 (en) * | 2018-04-19 | 2019-10-24 | Kibow Biotech Inc . | Composition and method for preventing or treating hyperuricemia or gout |
| CN109170917A (en) * | 2018-09-26 | 2019-01-11 | 广州市健全家源信息科技有限公司 | The compound of creatinine in a kind of reduction blood |
| CN110079476A (en) * | 2019-04-24 | 2019-08-02 | 杭州娃哈哈科技有限公司 | One plant of lactobacillus fermenti that can reduce blood uric acid |
| CN113215012A (en) * | 2020-01-21 | 2021-08-06 | 宁波倍益嘉生物科技有限公司 | Probiotic strain for reducing blood uric acid, composition and application thereof |
| CN113040363A (en) * | 2021-04-13 | 2021-06-29 | 青岛科技大学 | Seasoning with gout resisting function prepared by fermenting lactobacillus acidophilus |
Non-Patent Citations (2)
| Title |
|---|
| HSIEH等: "Screening and Evaluation of Purine-Nucleoside-Degrading Lactic Acid Bacteria Isolated fromWinemaking Byproducts In Vitro and Their Uric Acid-Lowering Effects In Vivo", FERMENTATION, vol. 7, no. 74, pages 1 - 13 * |
| ZHAO等: "The potential of probiotics in the amelioration of hyperuricemia", FOOD FUNCT., vol. 13, pages 2394 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115960775A (en) * | 2023-02-28 | 2023-04-14 | 吉林大学 | Lactobacillus salivarius for improving production performance of gosling and resisting gout |
| CN115960775B (en) * | 2023-02-28 | 2024-03-12 | 吉林大学 | Lactobacillus salivarius capable of improving productivity of gosling and resisting gout |
| CN117286077A (en) * | 2023-11-20 | 2023-12-26 | 微康益生菌(苏州)股份有限公司 | Probiotics for preventing and treating acute radioactive intestinal injury and application thereof |
| CN117286077B (en) * | 2023-11-20 | 2024-02-20 | 微康益生菌(苏州)股份有限公司 | Probiotics for preventing and treating acute radioactive intestinal injury and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101450511B1 (en) | Lactic acid bacteria having action of lowering blood uric acid level | |
| CN109810912B (en) | Lactobacillus plantarum LH-511 and application thereof | |
| CN115429820A (en) | Application of lactobacillus acidophilus in preparation of product for reducing blood uric acid | |
| CN114854643B (en) | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| CN113215012B (en) | Probiotic strain for reducing blood uric acid, composition and application thereof | |
| CN109810913B (en) | Lactobacillus rhamnosus ASD-9 and application thereof | |
| TWI764598B (en) | Reduction of purine content and uric acid level with lactobacillus plantarum tsp05 isolate | |
| KR101228035B1 (en) | New lactobacillus strains and compositions for preventing or treating diabetes comprising the same | |
| CA3131258A1 (en) | Composition for preventing, improving or treating obesity or fatty liver disease comprising the leuconostoc citreum wikim0104 | |
| CN116024130B (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
| CN114717147A (en) | Metazoan prepared from Lactobacillus rhamnosus and used for relieving fatty liver and obesity, and application thereof | |
| CN113249280B (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| CN114164130B (en) | Probiotics strain for reducing purine precursor, composition and application thereof | |
| CN115287240A (en) | Lactobacillus plantarum with hyperuricemia and gout prevention and treatment effects and application thereof | |
| CN115287239A (en) | Lactobacillus plantarum capable of degrading nucleosides and purines in vitro and reducing uric acid and application thereof | |
| CN113322216B (en) | Lactobacillus paracasei B111H and application thereof in metabolic syndrome | |
| US20190070204A1 (en) | Proliferative agent for faecalibacterium | |
| JP6654824B2 (en) | Blood uric acid level reducer | |
| CN116676210A (en) | Bifidobacterium animalis subspecies lactis for improving functional constipation and application thereof | |
| CN116286534A (en) | Lactobacillus plantarum for relieving hyperuricemia, and compound and application thereof | |
| CN115191607A (en) | Lactobacillus plantarum YU28 strain and application thereof | |
| CN114921383A (en) | Probiotic preparation with cholesterol removing function and preparation method thereof | |
| CN114686405A (en) | Bifidobacterium bifidum capable of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| CN117025456B (en) | Lactobacillus paracasei A21151 with blood uric acid reducing and anti-inflammatory effects and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |